Compare ClearPoint Neuro Inc (CLPT) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Qurate Retail Inc Series A — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Qurate Retail Inc Series A trades at $0.09 (market cap $1.05M). The key difference: ClearPoint Neuro Inc is far larger — about 455.8× Qurate Retail Inc Series A's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| CLPT | QVCAQ | |
|---|---|---|
Market Cap | $478.63M | $1.05M |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $15.03 |
52-Week Low | $8.66 | $0.07 |
Enterprise Value | $506.63M | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
QVCAQ trades at $0.082, down 9.99% today, with a bearish technical outlook showing 13 sell signals versus 3 buy signals. Fundamentally, the company reported a net loss of $2.44 billion in 2025 on $9.23 billion revenue, with negative shareholder equity of $971 million and concerning debt-to-asset ratio of 77.57%. Recent earnings show volatility with one beat and three misses in the last four quarters.
The stock faces significant headwinds from persistent losses, negative equity, and high leverage. While QVC's recent brand celebration shows ongoing operations, the financial deterioration and bearish technical indicators suggest caution. Recovery depends on sustainable profitability improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
